Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications

Abstract

Previous study revealed that microRNA (miR)-150 might function as a tumor suppressor in osteosarcoma partially by targeting Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1). The aim of this study was to investigate the clinical significance of miR-150-IGF2BP1 axis in human osteosarcoma which remains unclear. At first, expression levels of miR-150, and IGF2BP1 mRNA and protein in 20 osteosarcoma and matched adjacent noncancerous tissues were respectively detected by quantitative real-time PCR and western blot analyses. Then, subcellular localization and expression pattern of IGF2BP1 protein in 100 osteosarcoma tissues were examined by immunohistochemistry. Associations of miR-150/IGF2BP1 expression with various clinicopathological features and patients' prognosis were also statistically evaluated. As a result, miR-150 expression was significantly decreased, while IGF2BP1 mRNA and protein expression were dramatically increased in osteosarcoma tissues compared to matched adjacent noncancerous tissues (all P < 0.001). Immunostaining of IGF2BP1 protein was localized in cytoplasm of tumor cells in osteosarcoma tissues. Statistically, low miR-150 expression and/or high IGF2BP1 protein immunoreactive score were all significantly associated with high tumor grade, presence of metastasis and recurrence, as well as poor response to chemotherapy (all P < 0.05). Moreover, miR-150, IGF2BP1 and combined miR-150/IGF2BP1 expressions were all identified as independent prognostic factors for overall and disease-free survivals of osteosarcoma patients (all P < 0.05). In conclusion, our data suggest that miR-150 and its downstream target IGF2BP1 may be a crucial axis for the development, progression and patients' prognosis of ostesarcoma. The newly identified miR-150/IGF2BP1 axis might be a novel potential therapeutic target for osteosarcoma treatment.

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

“…We built regulatory networks with identified potential miRNA/gene and DMP/gene regulatory pairs, in which some pairs had been reported to exert positive effect on cancer pathogenesis and progression. For example, hsa-miR-150/ IGF2BP1 regulatory pair was reported to be a novel potential therapeutic target for osteosarcoma treatment ( 65 ), and IGF2BP1 was identified as a novel target gene of hsa-miR-98-5p in hepatocellular carcinoma ( 66 ). Similarly, the DNA demethylation in the promoter region of IGF2BP3 could influence the progression of G-CIMP gliomas ( 67 ), and cg07166550/ ALKBH5 could be used as prognostic biomarkers in prostate cancer ( 68 ).…”

Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis

“…In osteosarcoma, the expression of miR-10b and miR-146a has been related to tumor recurrence [62,63], and elevated levels of miR-21, miR-92a and miR-125b or low levels of miR-26a and miR-382 have been associated with poor prognosis [64,65,66]. Wang et al, have associated low levels of miR-150 with high tumor OS grade and poor response to chemotherapy [67].…”

Integrated Analysis of Nine Prognostic RNA-Binding Proteins in Soft Tissue Sarcoma

“…First, we obtained 329 differentially expressed RBPs. Among them, CDC5L (40) and IGF2BP1 (41) have been indicated to be biomarkers of osteosarcoma and affect the prognosis of osteosarcoma. To elucidate the underlying biomolecular mechanism of differentially expressed RBPs, we used GO and KEGG enrichment analyses.…”